Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Indirect treatment comparison of ivosidenib and other therapies in patients with newly diagnosed acute myeloid leukemia.

Future oncology (London, England) - 1 Jul 2025

Gil-Sierra Manuel David, Mantopoulos Theo, Barouma Ifigeneia, Hauch Ole, Teng Zhaoyang, Fernandez Cedric, Corbet Sean, Schlueter Max

Abstract excerpt

AIM: To assess the relative efficacy of ivosidenib + azacitidine versus other therapies (venetoclax, glasdegib, azacitidine, decitabine and low-dose cytarabine [LDAC]) for the treatment of patients with newly diagnosed IDH1-mutated (mIDH1) acute myeloid leukemia (AML) ineligible for intensive induction chemotherapy. METHODS: A systematic literature review (SLR) was conducted to identify evidence from studies...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antineoplastic Combined Chemotherapy Protocols
Share to Azacitidine

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Bridged Bicyclo Compounds, Heterocyclic

Share to Glycine

Share to Isocitrate Dehydrogenase

Share to Leukemia, Myeloid, Acute

Share to Pyridines

Share to Sulfonamides

Source

Open in PubMed Open full text

Identifiers

PMID: 40491347
DOI: 10.1080/14796694.2025.2515778
PMCID: PMC12239766

Genes

IDH1
EFS

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 8 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Indirect treatment comparison of ivosidenib and other therapies in patients with newly diagnosed acute myeloid leukemia.PMID 40491347Read ↗

Comparison of venetoclax and ivosidenib/enasidenib for unfit newly diagnosed patients with acute myeloid leukemia and IDH1/2 mutation: a network meta-analysis.Semantic proximity Read ↗

Matching-Adjusted Indirect Comparison of Olutasidenib and Ivosidenib in Isocitrate Dehydrogenase 1-Mutated Relapsed/Refractory Acute Myeloid Leukemia.Semantic proximity Read ↗

FDA Approval Summary: Ivosidenib in Combination with Azacitidine for Treatment of Patients with Newly Diagnosed Acute Myeloid Leukemia with an IDH1 Mutation.Semantic proximity Read ↗

Ivosidenib or venetoclax combined with hypomethylating agents in IDH1-mutated acute myeloid leukemia: a real-world studySemantic proximity Read ↗

Impact of Venetoclax and Azacitidine in Treatment-Naïve Patients with Acute Myeloid Leukemia and IDH1/2 Mutations.Semantic proximity Read ↗

A review of the isocitrate dehydrogenase inhibitors in management of adult patients with AML and MDS.Semantic proximity Read ↗

Ivosidenib induces deep durable remissions in patients with newly diagnosed IDH1-mutant acute myeloid leukemia.Semantic proximity Read ↗

Safety and efficacy of venetoclax-azacitidine combined with low-dose idarubicin and cytarabine regimens for the treatment of newly diagnosed acute myeloid leukemia patients compared to the standard chemotherapy: a propensity score-matched real- world single-center experienceSemantic proximity Read ↗

Efficacy and tolerability of isocitrate dehydrogenase inhibitors in patients with acute myeloid leukemia: A systematic review of clinical trials.Semantic proximity Read ↗

Real-life Multicenter Experience of Long-term Treatment With Venetoclax Plus Azacitidine for Acute Myeloid Leukemia in ChinaSemantic proximity Read ↗

Efficacy and safety of enasidenib and azacitidine combination in patients with IDH2 mutated acute myeloid leukemia and not eligible for intensive chemotherapy.Semantic proximity Read ↗

Outcomes of Frontline Triplet Regimens With a Hypomethylating Agent, Venetoclax, and Isocitrate Dehydrogenase Inhibitor for Intensive Chemotherapy-Ineligible Patients With Isocitrate Dehydrogenase-Mutated AML.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.